Diabetes News

The FDA is warning providers and patients that dosing errors with compounded injectable semaglutide may be leading to adverse events, according to a press release.

There are many important factors primary care providers must consider when prescribing popular anti-obesity medications, according to experts.

A voluntary medical device correction has been issued for a small number of continuous glucose monitoring sensors distributed in the first half of May, according to an industry press release.

Children with presymptomatic type 1 diabetes who had COVID-19 experienced higher rates of type 1 diabetes diagnoses than those who did not have COVID-19, according to recently published data.

Individuals who develop type 1 diabetes during childhood experienced greater risk for several mental health conditions later in life, including anxiety disorders and substance use disorders, study results showed.

New prescriptions of GLP-1 receptor agonists for the treatment of obesity have increased significantly among individuals without type 2 diabetes in the last decade, according to a study in Annals of Internal Medicine.

In a single-center cohort of patients with heart failure and obesity, weight-loss surgery led to improved clinical outcomes including reduced BMI and HbA1c and less reliance on diuretics, researchers reported.

Semaglutide was not associated with increased risks for adverse neurologic or psychological disorders at 1 year compared with other diabetes drugs, according to data published in eClinicalMedicine.

Adults with a sleep duration that varies by a mean of more than 1 hour each night may have an increased risk for developing diabetes, according to a study published in Diabetes Care.

Researchers found that adults with overweight or obesity lost more weight with tirzepatide than semaglutide in a head-to-head comparison of the medications using electronic medical records data.